Lipid composition and grafted PEG affect in vivo activity of liposomal mitoxantrone

International Journal of Pharmaceutics

Volumn 362, Issue 1-2, 2008, Pages 60-66

  Li, ChunLei ^a   Cui, JingXia ^b   Wang, CaiXia ^a   Wang, JinXu ^a   Li, YanHui ^a   Zhang, Lan ^a   Zhang, Li ^a   Guo, WenMin ^a   Wang, YongLi ^b  

^a Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd   (China)

^b HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Antitumor efficacy; Drug release; Lipid composition; Liposomes; Mitoxantrone; Polyethylene glycol grafting density; Toxicity

Indexed keywords

AMMONIUM SULFATE; LIPOSOME; MACROGOL; MITOXANTRONE;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; ENCAPSULATION; LIPID COMPOSITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

ACUTE TOXICITY TESTS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG COMPOUNDING; DRUG SCREENING ASSAYS, ANTITUMOR; LIPIDS; LIPOSOMES; MALE; MICE; MICE, INBRED BALB C; MITOXANTRONE; NEOPLASM TRANSPLANTATION; NEOPLASMS; PHOSPHATIDYLCHOLINES; POLYETHYLENE GLYCOLS; SOLUBILITY; TISSUE DISTRIBUTION;

EID: 50249145666     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.06.008     Document Type: Article

References (29)

1. Adlakha-Hutcheon G., Bally M.B., Shew C.R., and Madden T.D. Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity. Nat. Biotechnol. 17 (1999) 775-779
2. Ahmad A., Wang Y.F., and Ahmad I. Separation of liposome-entrapped mitoxantrone from nonliposomal mitoxantrone in plasma: pharmacokinetics in mice. Methods Enzymol. 391 (2005) 176-185
3. Chang C.W., Barber L., Ouyang C., Masin D., Bally M.B., and Madden T.D. Plasma clearance, biodistribution and therapeutic properties of mitoxantrone encapsulated in conventional and sterically stabilized liposomes after intravenous administration in BDF1 mice. Br. J. Cancer 75 (1997) 169-177
4. Cohen B.A., and Mikol D.D. Mitoxantrone treatment of multiple sclerosis: safety considerations. Neurology 63 (2004) S28-S32
5. Cui J., Li C., Guo W., Li Y., Wang C., Zhang L., Zhang L., Hao Y., and Wang Y. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?. J. Control. Release 118 (2007) 204-215
6. Drummond D.C., Meyer O., Hong K., Kirpotin D.B., and Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 51 (1999) 691-743
7. Fox E.J. Management of worsening multiple sclerosis with mitoxantrone: a review. Clin. Ther. 28 (2006) 461-474
8. Genne P., Olsson N.O., Gutierrez G., Duchamp O., and Chauffert B. Liposomal mitoxantrone for the local treatment of peritoneal carcinomatosis induced by colon cancer cells in mice. Anticancer Drug Des. 9 (1994) 73-84
9. Gokhale P.C., Pei J., Zhang C., Ahmad I., Rahman A., and Kasid U. Improved safety, pharmacokinetics and therapeutic efficacy profiles of a novel liposomal formulation of mitoxantrone. Anticancer Res. 21 (2001) 3313-3321
10. Johnson J.L., Ahmad A., Khan S., Wang Y.F., Abu-Qare A.W., Ayoub J.E., Zhang A., and Ahmad I. Improved liquid chromatographic method for mitoxantrone quantification in mouse plasma and tissues to study the pharmacokinetics of a liposome entrapped mitoxantrone formulation. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 799 (2004) 149-155
11. Kenworthy A.K., Hristova K., Needham D., and McIntosh T.J. Range and magnitude of the steric pressure between bilayers containing phospholipids with covalently attached poly(ethylene glycol). Biophys. J. 68 (1995) 1921-1936
12. Koeller J., and Eble M. Mitoxantrone: a novel anthracycline derivative. Clin. Pharm. 7 (1988) 574-581
13. Lim H.J., Masin D., Madden T.D., and Bally M.B. Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone. J. Pharmacol. Exp. Ther. 281 (1997) 566-573
14. Lim H.J., Masin D., McIntosh N.L., Madden T.D., and Bally M.B. Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors. J. Pharmacol. Exp. Ther. 292 (2000) 337-345
15. Lim H.J., Parr M.J., Masin D., McIntosh N.L., Madden T.D., Zhang G., Johnstone S., and Bally M.B. Kupffer cells do not play a role in governing the efficacy of liposomal mitoxantrone used to treat a tumor model designed to assess drug delivery to liver. Clin. Cancer Res. 6 (2000) 4449-4460
16. Madden T.D., Harrigan P.R., Tai L.C., Bally M.B., Mayer L.D., Redelmeier T.E., Loughrey H.C., Tilcock C.P., Reinish L.W., and Cullis P.R. The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. Chem. Phys. Lipids 53 (1990) 37-46
17. Martinelli Boneschi F, Rovaris M, Capra R, Comi G. Mitoxantrone for multiple sclerosis. Cochrane Database of Systematic Reviews 2005, Issue 4. Art. No.: CD002127.
18. Mike S., Harrison C., Coles B., Staffurth J., Wilt T.J., and Mason M.D. Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst. Rev. (2006) CD005247
19. Mills J.K., and Needham D. The materials engineering of temperature-sensitive liposomes. Methods Enzymol. 387 (2004) 82-113
20. Murray T.J. The cardiac effects of mitoxantrone: do the benefits in multiple sclerosis outweigh the risks?. Expert Opin. Drug Saf. 5 (2006) 265-274
21. Needham D., and Dewhirst M.W. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv. Drug Deliv. Rev. 53 (2001) 285-305
22. Neuhaus O., Kieseier B.C., and Hartung H.P. Therapeutic role of mitoxantrone in multiple sclerosis. Pharmacol. Ther. 109 (2006) 198-209
23. Pestalozzi B., Schwendener R., and Sauter C. Phase I/II study of liposome-complexed mitoxantrone in patients with advanced breast cancer. Ann. Oncol. 3 (1992) 445-449
24. Pestalozzi B.C., Vass A., Adam H., Horber D.H., Schwendener R.A., and Sauter C. Phase II study of liposome-complexed mitoxantrone in patients with advanced breast cancer. Eur. J. Cancer 31A (1995) 1024
25. Samad A., Sultana Y., and Aqil M. Liposomal drug delivery systems: an update review. Curr. Drug Deliv. 4 (2007) 297-305
26. Schwendener R.A., Fiebig H.H., Berger M.R., and Berger D.P. Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy. Cancer Chemother. Pharmacol. 27 (1991) 429-439
27. Tallman M.S., Gilliland D.G., and Rowe J.M. Drug therapy for acute myeloid leukaemia. Blood 106 (2005) 1154-1163
28. Ugwu S., Zhang A., Parmar M., Miller B., Sardone T., Peikov V., and Ahmad I. Preparation, characterization, and stability of liposome-based formulations of mitoxantrone. Drug Dev. Ind. Pharm. 31 (2005) 223-229
29. Wiseman L.R., and Spencer C.M. Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer. Drugs Aging 10 (1997) 473-485